Reuters - Video

Edition: US | UK | IN | CN | JP

video Breakingviews

Breakingviews TV: Biogen fail

Thursday, March 21, 2019 - 03:26

The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.

▲ Hide Transcript

View Transcript

The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Breakingviews TV: Biogen fail

Thursday, March 21, 2019 - 03:26